Movalis (Meloxicam)

Meloxicam works by selectively inhibiting the cyclooxygenase‑2 (COX‑2) enzyme, which reduces the production of prostaglandins that cause inflammation, pain, and fever. By targeting COX‑2 more than COX‑1, it provides anti‑inflammatory effects while sparing some protective gastric prostaglandins.

The appropriate dose of Movalis is determined by the prescribing healthcare professional based on the individual’s medical condition, age, renal and hepatic function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Movalis is classified as Pregnancy Category C, meaning risk cannot be ruled out and it should only be used if the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk, so breastfeeding mothers should consult their physician before using the product.

To order Movalis, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with non‑selective NSAIDs, meloxicam offers a higher degree of COX‑2 selectivity, which may result in a lower incidence of gastrointestinal irritation while still providing effective anti‑inflammatory and analgesic action. However, cardiovascular and renal risks remain similar to other NSAIDs and must be monitored.

Movalis tablets should be stored at ambient temperature below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiration date printed on the label.

Movalis is taken orally, usually with a glass of water. It can be taken with or without food, although taking it with food may reduce occasional stomach upset. The exact administration schedule is set by the prescribing clinician.

Serious risks associated with Movalis include gastrointestinal bleeding or ulceration, severe liver injury, renal failure, cardiovascular events such as heart attack or stroke, and rare but life‑threatening skin reactions. Patients should seek immediate medical attention if they experience symptoms like black stools, severe abdominal pain, jaundice, sudden swelling, or rash.

Movalis should be avoided in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal ulceration, severe heart failure, uncontrolled hypertension, or significant renal or hepatic impairment unless specifically directed by a physician.